Page 202 - 2021_05-Haematologica-web

V. Jachiet et al.
R, David Tai FW, Newland AC. Autologous
111 In-labelled platelet sequestration stud- ies in patients with primary immune thrombocytopenia (ITP) prior to splenecto- my: a report from the United Kingdom ITP Registry. Br J Haematol. 2010;151(5):477- 487.
26. Palandri F, Polverelli N, Catani L, et al. The choice of second-line therapy in steroid- resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long- term study. Am J Hematol. 2014;89(11): 1047-1050.
27. Mahevas M, Van Eeckhoudt S, Moulis G, et al. Autologous 111Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. Br J Haematol. 2019;186(3):e44-47.
28.Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombo- cytopenia. Cancer. 2014;120(12):1838- 1846.
29. Wang ES, Lyons RM, Larson RA, et al. A randomized, double-blind, placebo-con- trolled phase 2 study evaluating the effica- cy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol. 2012;5:71.
30. Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132(25):2629-2638.
31. Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018; 5(3):e117-126.
32. Vicente A, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. Haematologica. 2020;105(12): 2785-2794.
33. Oliva EN, Alati C, Santini V, et al. Long term effects of eltrombopag treatment ver- sus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL- MDS): interim results of a single-blind, ran- domised, controlled, phase 2 superiority trial. Blood. 2019;134(Suppl_1):3000.
34. Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol. 2014;167(5):626-638.
35. Dodillet H, Kreuzer K-A, Monsef I, Skoetz N. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2017;9(9): CD009883.
36. Erickson-Miller CL, Chadderton A, Gibbard A, et al. Thrombopoietin receptor levels in tumor cell lines and primary tumors. J Oncol. 2010;2010:135354.
37. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells
from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899-3908.
38. Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386-394.
39. Sugita M, Kalota A, Gewirtz AM, Carroll M. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression. Leukemia. 2013;27(5):1207-1210.
40. Liu X-G, Liu S, Feng Q, et al. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP. Blood. 2016;128(6):852-861.
41. Mekinian A, Grignano E, Braun T, et al. Systemic inflammatory and autoimmune manifestations associated with myelodys- plastic syndromes and chronic myelomonocytic leukaemia: a French mul- ticentre retrospective study. Rheumatology. 2016;55(2):291-300.
42. Dalamaga M, Petridou E, Cook FE, Trichopoulos D. Risk factors for myelodys- plastic syndromes: a case-control study in Greece. Cancer Causes Control. 2002;13(7): 603-608.
43. Marisavljević D, Kraguljac N, Rolović Z. Immunologic abnormalities in myelodys- plastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol. 2006;23(3):385-391.
44. Giannouli S, Kanellopoulou T, Voulgarelis M. Myelodysplasia and autoimmunity. Curr Opin Rheumatol. 2012;24(1):97-102.
1422
haematologica | 2021; 106(5)